Table 3.

Potential impact of cancer treatments on exercise tolerance and safety

		Surgery	Chemotherapy	Radiation	Anti-hormonal therapy (surgical or pharmaceutical)	Targeted Therapy or Immunotherapy a
Cardiovascular changes	Cardiac damage or increased CVD risk		√	√	√	√
Endocrine changes
	Worsening bone health		√	√	√
	Changes in body composition (weight gain)		√		√
	Changes in body composition (weight loss/muscle mass loss)	√	√	√	√	√
Gastrointestinal changes
	Nausea		√			√
	Diarrhea		√	√		√
	Altered GI function	√	√	√		√
Immune changes	Impaired immune function and/or anemia		√	√	√	√
Metabolic changes
	Development/worsening of metabolic syndrome		√		√	√ b
Neurological changes	Peripheral Neuropathy		√
	Cognitive changes	√ (brain surgery)	√	√	√
Pulmonary changes	Altered lung function or pneumonitis	√ (lung surgery)	√	√
Skin changes
	Redness, irritation			√
	Rashes			√		√
	Reduced ROM	√ (by healing at surgical site)		√
Fatigue		√	√	√	√	√
Lymphedema c		√		√
Pain	General	√	√	√	√	√
	Myalgia/Arthralgia		√		√	√

Adapted from Schmitz et al. ACSM 2010 Roundtable

Legend

^aDepends on type or target of agent

^bEspecially common with PI3kinase inhibitors

^cCan occur in any type of cancer when and where lymph nodes are surgically resected and/or radiation over lymph nodes.

Abbreviations: CVD, cardiovascular disease; GI, Gastrointestinal.